Canaccord Genuity analyst Edward Nash maintained a Buy rating on Akero Therapeutics (AKRO) yesterday and set a price target of $36.00. The company’s shares closed last Wednesday at $22.78.
According to TipRanks.com, Nash is a 4-star analyst with an average return of 7.0% and a 41.0% success rate. Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Galmed Pharmaceuticals, and Theratechnologies.
Currently, the analyst consensus on Akero Therapeutics is a Moderate Buy with an average price target of $34.50.
See today’s analyst top recommended stocks >>
Based on Akero Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.89 million. In comparison, last year the company had a GAAP net loss of $5.36 million.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AKRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
